TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23633524

Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 17

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 17
Study: 22099273

Group type: EXPERIMENTAL
Intervention: 81 mEq per day of oral potassium-sodium citrate (27 mEq three times a day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (untreated group)
Number of subjects: 76
Study: 18337330

Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant treatment
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control households (no treatment)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Follow-up on purchase and use of flocculant-disinfectant
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Randomized to intervention group
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Combined spending on laundry soap, toothpaste, and hand soap
Number of subjects: 257
Study: 17145742

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 4360

Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 4360

Group type: EXPERIMENTAL
Intervention: glyburide
Number of subjects: 4360
Study: 12689805

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (two 45‐min counseling sessions plus two brief follow‐up telephone contacts)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Control intervention unrelated to diet
Number of subjects: 616
Study: 10773056

Group type: EXPERIMENTAL
Intervention: Pooled random-donor platelets (PP) transfusions during Study Period B (≤3-day-old PPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled random-donor platelets (PP) transfusions during Study Period A (older PPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-donor apheresis platelets (SDP) transfusions during Study Period B
Number of subjects: 0
Study: 9003855

Group type: EXPERIMENTAL
Intervention: Deferoxamine administered by twice‐daily subcutaneous injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional administration by prolonged subcutaneous infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total daily dose administered as a single injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of deferoxamine
Number of subjects: 20
Study: 1488663

Group type: EXPERIMENTAL
Intervention: Combined therapy (colloidal bismuth subcitrate and ampicillin)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (CBS) therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ampicillin therapy
Number of subjects: 48
Study: 3698065

Group type: EXPERIMENTAL
Intervention: One 500-mg clotrimazole vaginal tablet for one day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Two 100-mg clotrimazole vaginal tablets daily for three days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Three-day treatment group
Number of subjects: 42
Study: 29878043

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose (25% wt:vol, ∼1400 mOsmol/L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intraduodenal sucralose (4 mmol/L, ∼300 mOsmol/L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intraduodenal saline (0.9% wt:vol, ∼300 mOsmol/L)
Number of subjects: 12
Study: 27281699

Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation (2.9 g/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24370819

Group type: EXPERIMENTAL
Intervention: Active motor rehabilitation treatment based on voluntary exercises including task-oriented exercises.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive mobilization of the shoulder, elbow, wrist and fingers (Control group).
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (Active and Control).
Number of subjects: 30
Study: 22729935

Group type: EXPERIMENTAL
Intervention: Construction laborers
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Motor freight workers
Number of subjects: 1555
Study: 20723644

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 476

Group type: COMPARATOR
Intervention: Magnesium sulfate (5 g IV for 1 hour, followed by ibutilide and another 5 g for 2 additional hours)
Number of subjects: 476
Study: 19004414

Group type: EXPERIMENTAL
Intervention: Low doses of MDMA (50-75 mg)
Number of subjects: 6
Study: 15879361

Group type: EXPERIMENTAL
Intervention: Metformin (1700 mg daily) for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal women of similar age and BMI), N=20
Number of subjects: 20
Study: 12569213

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (4 sets of 2-min contractions at 30% maximum voluntary contraction, 3 times per week for 10 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (8 subjects)
Number of subjects: 17
Study: 11712446

Group type: EXPERIMENTAL
Intervention: Heparin and aspirin (Group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Streptokinase, heparin, and aspirin (Group B)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 29
Study: 8634167

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1323616

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg orally five times daily for 5 days after UV exposure, starting 1 day before exposure.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched placebo, administered similarly to acyclovir group.
Number of subjects: 24
Study: 6361005

Group type: EXPERIMENTAL
Intervention: maprotiline
Number of subjects: 49

Group type: COMPARATOR
Intervention: doxepin
Number of subjects: 49
Study: 30922327

Group type: EXPERIMENTAL
Intervention: Codrituzumab
Number of subjects: 0
Study: 28093132

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (CRO) with standard analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard anaesthetic procedure (Control group)
Number of subjects: 60
Study: 25861682

Group type: EXPERIMENTAL
Intervention: Test toothbrush (TB1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control toothbrush (TB2)
Number of subjects: 10
Study: 23806032

Group type: EXPERIMENTAL
Intervention: Carbogen (5% CO2 plus 95% O2)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo (100% O2)
Number of subjects: 288
Study: 21081908

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg once daily for 7 days)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Aspirin-phosphatidylcholine (PL2200, 325 mg once daily for 7 days)
Number of subjects: 204
Study: 19951570

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial integrated therapy targeting hyperglycemia, hypertension, dyslipidemia, and aspirin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional outpatient treatment
Number of subjects: 150
Study: 17289766

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg once daily for 7 days
Number of subjects: 119

Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice daily for 7 days
Number of subjects: 119
Study: 15370020

Group type: EXPERIMENTAL
Intervention: Start Over and Survive (SOS) intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 25
Study: 16351363

Group type: EXPERIMENTAL
Intervention: Stereotype threat manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 9828271

Group type: EXPERIMENTAL
Intervention: 0.25 mg intravenous glucagon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous glucagon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 mg intravenous glucagon
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.25 mg and 0.5 mg intravenous glucagon
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.5 mg and 1 mg intravenous glucagon
Number of subjects: 10
Study: 7569009

Group type: EXPERIMENTAL
Intervention: Cisplatin plus radiation (n = 13)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cisplatin alone (n = 10)
Number of subjects: 23
Study: 1658875

Group type: EXPERIMENTAL
Intervention: Monopic porcine insulin (proinsulin less than 10 ppm)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Human insulin (proinsulin less than 1 ppm)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bovine insulin (proinsulin less than 3,000 ppm)
Number of subjects: 28
Study: 7148360

Group type: EXPERIMENTAL
Intervention: Metoclopramide given before anaesthesia
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 30593882

Group type: EXPERIMENTAL
Intervention: Chat-based instant messaging support combined with brief interventions for smoking cessation
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Brief advice to quit plus a self-help booklet at baseline
Number of subjects: 1172
Study: 28117264

Group type: EXPERIMENTAL
Intervention: Ankle balance taping (ABT) with kinesiology tape
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 15

Group type: COMPARATOR
Intervention: No taping
Number of subjects: 15
Study: 26849270

Group type: EXPERIMENTAL
Intervention: Benzene exposure
Number of subjects: 317

Group type: COMPARATOR
Intervention: Control group (non-exposed)
Number of subjects: 317
Study: 25456420

Group type: EXPERIMENTAL
Intervention: Gamisoyo-San multi-compound extract
Number of subjects: 147

Group type: COMPARATOR
Intervention: Gamisoyo-San individual extract mixture
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 21920532

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 59
Study: 19170780

Group type: EXPERIMENTAL
Intervention: Mobile film unit
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Mobile digital unit
Number of subjects: 499

Group type: COMPARATOR
Intervention: Stationary unit
Number of subjects: 499
Study: 17254923

Group type: EXPERIMENTAL
Intervention: Surgical score based on estimated blood loss, lowest heart rate, and lowest mean arterial pressure
Number of subjects: 1070
Study: 16321601

Group type: EXPERIMENTAL
Intervention: Vinegar
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Peanut products
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 11
Study: 11932288

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg.d rhIGF-I/IGFBP-3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg/kg.d rhIGF-I/IGFBP-3
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9871948

Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR) group, with 5 hours in bed
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CTRL) group, with 11 hours in bed
Number of subjects: 16
Study: 8537870

Group type: EXPERIMENTAL
Intervention: 5% sanguinarium (ABDS-S)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (oral hygiene quadrant)
Number of subjects: 17
Study: 31292267

Group type: EXPERIMENTAL
Intervention: RCT (Radiochemotherapy)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: RCT + RHT (Radiochemotherapy + Regional Hyperthermia)
Number of subjects: 369

Group type: COMPARATOR
Intervention: RT (Radiotherapy)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: RCT
Number of subjects: 369

Group type: COMPARATOR
Intervention: RT
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: RCT + RHT
Number of subjects: 369

Group type: COMPARATOR
Intervention: RCT + RHT vs RCT
Number of subjects: 369
Study: 29355162

Group type: EXPERIMENTAL
Intervention: Intravenous 0.25 mg/kg dexamethasone in 5 ml solution
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 94
Study: 25615272

Group type: EXPERIMENTAL
Intervention: 7-min language samples
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10-min language samples
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1-min and 3-min language samples
Number of subjects: 60

Group type: COMPARATOR
Intervention: 22-min language samples
Number of subjects: 60
Study: 23591400

Group type: EXPERIMENTAL
Intervention: Topotecan, cisplatin, and bevacizumab
Number of subjects: 27
Study: 21284406

Group type: EXPERIMENTAL
Intervention: palonosetron 0.5 μg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: palonosetron 1.0 μg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: palonosetron 1.5 μg/kg
Number of subjects: 150
Study: 17034926

Group type: EXPERIMENTAL
Intervention: Metallic matrix and wooden wedge
Number of subjects: 23

Group type: COMPARATOR
Intervention: Polyester matrix and reflective wedge
Number of subjects: 23
Study: 16234576

Group type: EXPERIMENTAL
Intervention: Hydrogel wound dressing containing a combination of endopeptidases
Number of subjects: 10
Study: 12704989

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy and physical preventive therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clinical follow-up only
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Microsurgical operation of lymphatic-venous anastomoses
Number of subjects: 50
Study: 10070130

Group type: EXPERIMENTAL
Intervention: Atropine infusion [0.4 mg/m2 bolus, 0.4 mg. (m2)‐1. h‐1] for 2 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atropine infusion
Number of subjects: 12
Study: 7737228

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg.kg‐1 h‐1, n = 32)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nitroglycerin (1 microgram.kg‐1 min‐1, n = 34)
Number of subjects: 66
Study: 2344229

Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg capsules t.i.d.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg capsules t.i.d.
Number of subjects: 27
Study: 7329736

Group type: EXPERIMENTAL
Intervention: 25 trials of continuous reinforcement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 trials of 25% partial reinforcement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional noninformed extinction (informed half)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Informed extinction (thermal stimulator removed)
Number of subjects: 40
Study: 30169738

Group type: EXPERIMENTAL
Intervention: Frontal subdural drain
Number of subjects: 577

Group type: COMPARATOR
Intervention: Parietal subdural drain
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Subdural drain
Number of subjects: 577

Group type: COMPARATOR
Intervention: Subgaleal drain
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Postoperative drainage for 1 day
Number of subjects: 577

Group type: COMPARATOR
Intervention: Postoperative drainage for 2 days
Number of subjects: 577
Study: 29020189

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 μg/kg) administered every 3 months for 3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 μg/kg) administered annually for 3 years
Number of subjects: 0
Study: 25720986

Group type: EXPERIMENTAL
Intervention: Two-piece implants
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One-piece implants
Number of subjects: 60
Study: 24361312

Group type: EXPERIMENTAL
Intervention: Mindfulness exercise (body scan)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (audio book)
Number of subjects: 110
Study: 23271901

Group type: EXPERIMENTAL
Intervention: OT group (trained obesity group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: AWT group (trained appropriate weight group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: OWT group (trained overweight group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All trained groups (AWT, OWT, OT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: C groups (AWC, OWC, OC)
Number of subjects: 70
Study: 19827649

Group type: EXPERIMENTAL
Intervention: Lipantil 200M (phenofibrate) 200 mg for 12 weeks
Number of subjects: 26
Study: 17396620

Group type: EXPERIMENTAL
Intervention: Emilok (test formulation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Commercially available original preparation (reference formulation)
Number of subjects: 36
Study: 16285942

Group type: EXPERIMENTAL
Intervention: Sequential treatment (omeprazole plus amoxicillin for 5 days, followed by omeprazole plus clarithromycin plus tinidazole for another 5 days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Triple therapy (omeprazole, amoxicillin, and metronidazole for 1 week)
Number of subjects: 78
Study: 12045680

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention plus standard HIV test counseling
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard HIV test counseling
Number of subjects: 248
Study: 9564988

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg orally once daily for 10 to 14 days
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 329
Study: 8770707

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPEX)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (immunosuppressive drug regimen without TPEX)
Number of subjects: 6
Study: 1978473

Group type: EXPERIMENTAL
Intervention: remoxipride (75‐375 mg daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: thioridazine (150‐750 mg daily)
Number of subjects: 61
Study: 365205

Group type: EXPERIMENTAL
Intervention: Salicylates (3.9 g per day)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Homoeopathy
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 30146682

Group type: EXPERIMENTAL
Intervention: NHSDP (NGO Health Services Delivery Project)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: MOHFW (Ministry of Health and Family Welfare)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Overall responsiveness
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Domains of responsiveness
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Recommendations
Number of subjects: 810
Study: 29482107

Group type: EXPERIMENTAL
Intervention: SafeCare intervention
Number of subjects: 294

Group type: COMPARATOR
Intervention: Child welfare services as usual
Number of subjects: 294
Study: 26843390

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 40
Study: 24595630

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily
Number of subjects: 40
Study: 22088831

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 8844

Group type: COMPARATOR
Intervention: CT colonography
Number of subjects: 8844
Study: 19514558

Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 2 mg terazosin
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine plus 2 mg terazosin
Number of subjects: 360
Study: 17430981

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Off stimulation condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: On stimulation condition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study: 15625213

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12198056

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 micrograms plus magnesium sulfate 50 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intrathecal fentanyl 25 micrograms plus saline
Number of subjects: 52
Study: 10426640

Group type: EXPERIMENTAL
Intervention: Modified Joel-Cohen technique
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pfannenstiel technique
Number of subjects: 72
Study: 8524989

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 27
Study: 2181788

Group type: EXPERIMENTAL
Intervention: telenzepine 3 mg nocte
Number of subjects: 163

Group type: COMPARATOR
Intervention: ranitidine 300 mg nocte
Number of subjects: 163
Study: 6769448

Group type: EXPERIMENTAL
Intervention: Doxapram 2 mg ml‐1
Number of subjects: 53

Group type: COMPARATOR
Intervention: 5% dextrose alone
Number of subjects: 53
Study: 31995812

Group type: EXPERIMENTAL
Intervention: Ketamine treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Baseline GBC
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GBC preprocessing with GSR
Number of subjects: 28
Study: 29047145

Group type: EXPERIMENTAL
Intervention: Patient-specific opioid dosing protocol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Weight-based opioid dosing protocol
Number of subjects: 52
Study: 27496180

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy added to treatment as usual
Number of subjects: 487

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 487
Study: 24138344

Group type: EXPERIMENTAL
Intervention: Buccalized occlusion (BO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fully bilateral balanced occlusion (BBO)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lingualized occlusion
Number of subjects: 15
Study: 23427393

Group type: EXPERIMENTAL
Intervention: Intravenous Xuebijing plus conventional therapy (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional therapy (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 36
Study: 21078806

Group type: EXPERIMENTAL
Intervention: (123)I‐FP‐CIT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Citalopram infusion (blocking SERT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: (123)I‐PE2I
Number of subjects: 16
Study: 18818895

Group type: EXPERIMENTAL
Intervention: Lumbar total disc replacement
Number of subjects: 3180
Study: 15806416

Group type: EXPERIMENTAL
Intervention: Methadone (100 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Buprenorphine (32.40+/‐2.8 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both Methadone and Buprenorphine
Number of subjects: 62
Study: 12821550

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement with CMR in patients with CAD (27 patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement with CMR in patients with DCM (63 patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (15 subjects)
Number of subjects: 90